# TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation

> **NCT05091723** · PHASE1 · COMPLETED · sponsor: **Theravance Biopharma** · enrollment: 14 (actual)

## Conditions studied

- Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)

## Interventions

- **DRUG:** Nezulcitinib (TD-0903) Dose A
- **DRUG:** Nezulcitinib (TD-0903) Dose B

## Key facts

- **NCT ID:** NCT05091723
- **Lead sponsor:** Theravance Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-13
- **Primary completion:** 2021-11-24
- **Final completion:** 2021-11-24
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2021-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05091723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05091723, "TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05091723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*